Vivus (VVUS) urges shareholders to re-elect the current board, arguing that First Manhattan's...

|By:, SA News Editor

Vivus (VVUS) urges shareholders to re-elect the current board, arguing that First Manhattan's plan for the company is "woefully short on details" and contains the same ideas Vivus is already implementing. First Manhattan says that former AstraZeneca exec Anthony Zook has agreed to be Vivus CEO if the activist investor prevails in the shareholder vote in just under two weeks. The cause of Vivus' current management can't have been helped by an NYT article profiling the failure of the firm's Qsymia weight-loss drug to take off since its launch in September.